NEWS RELEASE

FDA ADVISORY COMMITTEE DOES NOT RECOMMEND APPROVAL OF SIRUKUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS

8/2/2017